Probiotics-Derived Peptides and Their Immunomodulatory Molecules Can Play a Preventive Role Against Viral Diseases Including COVID-19
Tóm tắt
As of recent, the pandemic episode of COVID-19, a severe acute respiratory syndrome brought about by a novel coronavirus (SARS-CoV-2) expanding the pace of mortality, has affected the disease rate profoundly. Invulnerability is the fundamental choice to prevent the ruining event of COVID-19, as the drugs and antibodies are in the phase of preliminary clinical trials. Within this brief period, a few strains of SARS-CoV-2 have been recognized by the vaccine manufacturers, which could be an incorrect guess about the strain that will end up spreading. Since the circulating SARS-CoV-2 strains continue to mutate, immunizations, if at all works, might be for a restricted time. We have not put sufficient time in research to understand the immune responses that correlate with protection as this could help refine vaccines. Here, we have summed up the adequacy of the immunomodulatory component of probiotics for the prevention against viral infections. Furthermore, an in silico data have been provided in support of the “probiotics-derived lipopeptides” role in inactivating spike (S) glycoprotein of SARS-CoV-2 and its host receptor molecule, ACE2. Among well characterized lipopeptides derived from different probiotic strains, subtilisin (Bacillus amyloliquefaciens), curvacin A (Lactobacillus curvatus), sakacin P (Lactobacillus sakei), lactococcin Gb (Lactococcus lactis) was utilized in this study to demonstrate a higher binding proclivity to S-protein of SARS-CoV-2 and human ACE2. The outcome revealed noteworthy capabilities of the lipopeptides, due to their amphiphilic nature, to bind spike protein and receptor molecule, which may act to competitively inhibit the mandatory interaction of SARS-CoV-2 with the host epithelial cell expressing ACE2 for its entry into the cell for reproduction. In the current situation, probiotic treatment alongside chemotherapy may assist in bringing about substantial improvement of the health of COVID-19 patients. At the same time, probiotics may aid towards building up the immune defenses in people to evade COVID-19.
Tài liệu tham khảo
Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P (2008) Global trends in emerging infectious diseases. Nature 451:990–993. https://doi.org/10.1038/nature06536
Rather IA, Lone JB, Bajpai VK, Paek WK, Lim J (2017) Zika virus: an emerging worldwide threat. Front Microbiol 8:1417. https://doi.org/10.3389/fmicb.2017.01417
Mandal SM, Manna S, Mondal S, Ghosh AK, Chakraborty R (2018) Transcriptional regulation of human defense peptides: a new direction in infection control. Biol Chem 399(11):1277–1284. https://doi.org/10.1515/hsz-2018-0182
Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140(6):543–546. https://doi.org/10.1001/archpedi.1986.02140200053026
Vijayanand P, Wilkins E, Woodhead M (2004) Severe acute respiratory syndrome (SARS): a review. Clin Med (Lond) 4(2):152–160. https://doi.org/10.7861/clinmedicine.4-2-152
Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, Huang J, He N, Yu H, Lin X, Wei S, Wu T (2020) Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA 323(19):1915–1923. https://doi.org/10.1001/jama.2020.6130
Bahadoran A, Lee SH, Wang SM, Manikam R, Rajarajeswaran J, Raju CS, Sekaran SD (2016) Immune responses to influenza virus and its correlation to age and inherited factors. Front Microbiol 7:1841. https://doi.org/10.3389/fmicb.2016.01841
Paul D, Manna S, Mandal SM (2018) Antibiotics associated disorders and post-biotics induced rescue in gut health. Curr Pharm Des 24(7):821–829. https://doi.org/10.2174/1381612824666171227221731
Eguchi K, Fujitani N, Nakagawa H, Miyazaki T (2019) Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055. Sci Rep 9:4812. https://doi.org/10.1038/s41598-019-39602-7
Weiss G, Rasmussen S, Zeuthen LH, Nielsen BN, Jarmer H, Jespersen L, Frokiaer H (2010) Lactobacillus acidophilus induces virus immune defense genes in murine dendritic cel is by a toll-like receptor-2-dependent mechanism. Immunology 131(2):268–281. https://doi.org/10.1111/j.1365-2567.2010.03301.x
Gabryszewski SJ, Bachar O, Dyer KD, Percopo CM, Killoran KE, Domachowske JB, Rosenberg HF (2011) Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. J Immunol 186(2):1151–1161. https://doi.org/10.4049/jimmunol.1001751
Berggren A, Lazou-Ahren I, Larsson N, Onning G (2011) Randomised, double-blind and place be controlled study using new probiotic lactobacilli for strengthening the body immune defense against viral infections. Eur J Nutr 50(3):203–210. https://doi.org/10.1007/s00394-010-0127-6
Pimentel-Nunes P, Soares JB, Roncon-Albuquerque R Jr, Dinis-Ribeiro M, Leite-Moreira AF (2010) Toll-like receptors as therapeutic targets in gastrointestinal diseases. Expert OpinTher Targets 14(4):347–368. https://doi.org/10.1517/14728221003642027
MacDonald TT, Monteleone I, Fantini MC, Monteleone G (2011) Regulation of homeostasis and inflammation in the intestine. Gastroenterology 140(6):1768–1775. https://doi.org/10.1053/j.gastro.2011.02.047
Wan LY, Chen ZJ, Shah NP, El-Nezami H (2016) Modulation of intestinal epithelial defense responses by probiotic bacteria. Crit Rev Food Sci Nutr 56(16):2628–2641. https://doi.org/10.1080/10408398.2014.905450
Salminen S, Nybom S, Meriluoto J, Collado MC, Vesterlund S, Nezami HE (2010) Interaction of probiotics and pathogens-benefits to human health? Curr Opin Biotechnol 21(2):157–167. https://doi.org/10.1016/j.copbio.2010.03.016
Kassaa I, Hober D, Hamze M, Chihib NE, Drider D (2014) Antiviral potential of lactic acid bacteria and their bacteriocins. Probiotics Antimicrob Proteins 6(3–4):177–185. https://doi.org/10.1007/s12602-014-9162-6
Rodrıguez-Dıaz J, Monedero V (2013) Probiotics against digestive tract viral infections. In: Watson RR, Preedy VR (eds) Bioactive food as dietary interventions for liver and gastrointestinal disease. Elsevier, San Diego, pp 271–284. https://doi.org/10.1016/B978-0-12-397154-8.00031-2
Zabihollahi R, Motevaseli E, Sadat SM, Azizi-Saraji AR, Asaadi-Dalaie S, Modarressi MH (2012) Inhibition of HIV and HSV infection by vaginal lactobacilli in vitro and in vivo. Daru 20(1):53. https://doi.org/10.1186/2008-2231-20-53
Kanauchi O, Andoh A, AbuBakar S, Yamamoto N (2018) Probiotics and paraprobiotics in viral infection: clinical application and effects on the innate and acquired immune systems. Curr Pharm Des 24(6):710–717. https://doi.org/10.2174/1381612824666180116163411
Lee DK, Kang JY, Shin HS, Park IH, Ha NJ (2013) Antiviral activity of Bifidobacterium adolescentis SPM0212 against hepatitis b virus. Arch Pharm Res 36(12):1525–1532. https://doi.org/10.1007/s12272-013-0141-3
Kim MJ, Lee DK, Park JE, Park IH, Seo JG, Ha NJ (2014) Antiviral activity of Bifidobacterium adolescentis SPM1605 against coxsackievirus B3. Biotechnol Biotechnol Equip 28(4):681–688. https://doi.org/10.1080/13102818.2014.945237
Botic T, Klingberg TD, Weingart H, Cencic A (2007) A novel eukaryotic cell culture model to study antiviral activity of potential probiotic bacteria. Int J Food Microbiol 115(2):227–234. https://doi.org/10.1016/j.ijfoodmicro.2006.10.044
Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A (2012) Probiotic mechanisms of action. Ann Nutr Metab 61(2):160–174. https://doi.org/10.1159/000342079
Varyukhina S, Freitas M, Bardin S, Robillard E, Tavan E, Sapin C, Grill JP, Trugnan G (2012) Glycan-modifying bacteria-derived soluble factors from Bacteroides thetaiotaomicron and Lactobacillus casei inhibit rotavirus infection in human intestinal cells. Microbes Infect 14(3):273–278. https://doi.org/10.1016/j.micinf.2011.10.007
Savan R, Sakai M (2006) Genomics of fish cytokines. Comp Biochem Phys D 1(1):89–101. https://doi.org/10.1016/j.cbd.2005.08.005
Foligné B, Dewulf J, Breton J, Claisse O, Lonvaud-Funel A, Pot B (2010) Probiotic properties of non-conventional lactic acid bacteria: immunomodulation by Oenococcus oeni. Int J Food Microbiol 140(2–3):136–145. https://doi.org/10.1016/j.ijfoodmicro.2010.04.007
Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D (2008) Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 10(1–2):37–54
Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ (1999) Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 274(25):17406–17409. https://doi.org/10.1074/jbc.274.25.17406
Kourelis A, Zinonos I, Kakagianni M, Christidou A, Christoglou N, Yiannaki E, Testa T, Kotzamanidis C, Litopoulou-Tzanetaki E, Tzanetakis N, Yiangou M (2010) Validation of the dorsal air pouch model to predict and examine immunostimulatory responses in the gut. J Appl Microbiol 108(1):274–284. https://doi.org/10.1111/j.1365-2672.2009.04421.x
Galdeano CM, Perdigón G (2006) The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 13(2):219–226. https://doi.org/10.1128/CVI.13.2.219-226.2006
Anderson KV (2000) Toll signalling pathways in the innate immune response. Curr Opin Immunol 12(1):13–19. https://doi.org/10.1016/s0952-7915(99)00045-x
Zhang B, Chassaing B, Shi Z, Uchiyama R, Zhang Z, Denning TL, Crawford SE, Pruijssers AJ, Iskarpatyoti JA, Estes MK, Dermody TS, Ouyang W, Williams IR, Kumar MV, Gewirtz AT (2014) Prevention and cure of rotavirus infection viaTLR5/NLRC4- mediated production of IL-22 and IL-18. Science 346(6211):861–865. https://doi.org/10.1126/science.1256999
Rigo-Adrover MDM, van Limpt K, Knipping K, Garssen J, Knol J, Costabile A, Franch À, Castell M, Pérez-Cano FJ (2018) Preventive effect of a synbiotic combination of galacto and fructooligosaccharides mixture with Bifidobacterium breve M-16V in a model of multiple rotavirus infections. Front Immunol 9:1318. https://doi.org/10.3389/fimmu.2018.01318
Monedero V, Buesa J, Rodríguez-Díaz J (2018) The interactions between host glycobiology, bacterial microbiota, and viruses in the gut. Viruses 10(2):96. https://doi.org/10.3390/v10020096
Servin AL (2004) Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 28(4):405–440. https://doi.org/10.1016/j.femsre.2004.01.003
Bodera P, Chcialowski A (2009) Immunomodulatory effect of probiotic bacteria. Recent Patents Inflamm Allergy Drug Discov 3(1):58–64. https://doi.org/10.2174/187221309787158461
Guarino A, Lo Vecchio A, Canani RB (2009) Probiotics for prevention and treatment of diarrhea. Curr Opin Gastroenterol 25(1):18–23. https://doi.org/10.1097/MCG.0000000000000349
Goto H, Sagitani A, Ashida N, Kato S, Hirota T, Shinoda T, Yamamoto N (2013) Anti-influenza virus effects of both live and non-live Lactobacillus acidophilus L-92 accompanied by the activation of innate immunity. Br J Nutr 110(10):1810–1818. https://doi.org/10.1017/S0007114513001104
Iwabuchi N, Xiao JZ, Yaeshima T, Iwatsuki K (2011) Oral administration of Bifidobacterium longum ameliorates influenza virus infection in mice. Biol Pharm Bull 34(8):1352–1355. https://doi.org/10.1248/bpb.34.1352
Wu S, Jiang ZY, Sun YF, Yu B, Chen J, Dai CQ, Wu XL, Tang XL, Chen XY (2013) Microbiota regulates the TLR7 signalling pathway against respiratory tract influenza a virus infection. Curr Microbiol 67(4):414–422. https://doi.org/10.1007/s00284-013-0380-z
Garcia-Crespo KE, Chan CC, Gabryszewski SJ, Percopo CM, Rigaux P, Dyer KD, Domachowske JB, Rosenberg HF (2013) Lactobacillus priming of the respiratory tract: heterologous immunity and protection against lethal pneumovirus infection. Antivir Res 97(3):270–279. https://doi.org/10.1016/j.antiviral.2012.12.022
Lehtoranta L, Pitkäranta A, Korpela R (2014) Probiotics in respiratory virus infections. Eur J Clin Microbiol Infect Dis 33(8):1289–1302. https://doi.org/10.1007/s10096-014-2086-y
Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ (2005) PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 33(Web Server issue):W363–W367. https://doi.org/10.1093/nar/gki481
Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M (2015) PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res 43(W1):W443–W447. https://doi.org/10.1093/nar/gkv315
Chowdhury T, Roymahapatra G, Mandal SM (2020) In Silico identification of a potent arsenic based approved drug darinaparsin against SARS-CoV-2: inhibitor of RNA dependent RNA polymerase (RdRp) and essential proteases. Infect Disord Drug Targets 20. https://doi.org/10.2174/1871526520666200727153643
Markland FS, Smith EL (1971) Subtilisins: primary structure, chemical and physical properties. In: Boyer PD (ed) The Enzymes. 3, 3rd edn. Academic Press, New York, pp 561–608
Tichaczek PS, Nissen-Meyer J, Nes IF, Vogel RF, Hammes WP (1992) Characterization of the bacteriocins curvacin a from Lactobacillus curvatus LTH1174 and sakacin P from L. sake LTH673. Syst Appl Microbiol 15(3):460–468. https://doi.org/10.1016/S0723-2020(11)80223-7
Moll G, Ubbink-Kok T, Hildeng-Hauge H, Nissen-Meyer J, Nes IF, Konings WN, Driessen AJ (1996) Lactococcin G is a potassium ion-conducting, two-component bacteriocin. J Bacteriol 178(3):600–605. https://doi.org/10.1128/jb.178.3.600-605.1996